Drugs / MTL-CEBPA
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05097911 | Aug 2021 → Apr 2026 overdue | hepatocellular carcinoma | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04105335 | Nov 2019 → Jan 2025 | cancer | Mina Alpha Limited | Completed | No outcome recorded |
| Phase 1 | NCT02716012 | Mar 2016 → Jul 2025 | hepatocellular carcinoma | Mina Alpha Limited | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04710641 | Jan 2022 → Jan 2025 | hepatitis B virus infection, hepatitis C virus infection, hepatocellular carcinoma | Mina Alpha Limited | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTL-CEBPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02716012 ↗ |
| Action | Activate | “upregulates C/EBP-α” PMID 32357963 ↗ May 2020 |
| Modality | Small activating RNA (saRNA) | “small activating RNA oligonucleotide drug” PMID 32357963 ↗ May 2020 |
| Route | Intravenous | “Intravenous administration” NCT02716012 ↗ |
| Target | CEBPA | “MTL-CEBPA is administered as monotherapy or in combination with sorafenib to patients with advanced hepatocellular carcinoma and cirrhosis of the liver. All participants will...” NCT02716012 ↗ |